

I hereby certify that on July 31, 2006, which is the date I am signing this certificate, I am electronically transmitting this correspondence and all identified attachments to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/Andrew Lee/

Andrew Lee

Applicant: **SUH, Pann-Ghill et al.**  
Serial No.: **N/A (PCT/KR2005/000329)**  
Filed: **Herewith**  
Confirmation No.: **N/A**  
Title: **PEPTIDES THAT ANTAGONIZE FPR CLASS RECEPTOR MEDIATED SIGNALING**  
Examiner: **N/A**  
Art Unit: **N/A**  
Attorney Docket No.: **20010-21USA**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner.

English Language Patent Documents:

US2003/0096260 A1, May 22, 2003
---------------------------------

US2003/0203841 A1, October 30, 2003
-------------------------------------

English Language Non-Patent Documents:

BAE ET AL., "Differential Activation of Formyl Peptide Receptor-Like 1 by Peptide Ligands," Journal of Immunology, 171:12 6807-6813 (2003).
BAE ET AL., "Differential Activation of Formyl Peptide Receptor Signlaing by Peptide Ligands," Molecular Pharmacology, 64:4 841-847 (2003).
BAE ET AL., "Identification of Peptides That Antagonize Formyl Peptide Receptor-Like 1-Mediated Signaling," Journal of Immunology, 173:1 607-614 (2004).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

Date: July 31, 2006

\_\_\_\_\_/Joseph Hyosuk Kim/\_\_\_\_\_  
Joseph Hyosuk Kim, Ph.D.  
Reg. No. 41,425  
Attorney for Applicants

**JHK Law**  
P.O. Box 1078  
La Canada, CA 91012-1078  
Telephone: (818) 249-8177  
Facsimile: (818) 249-8277

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(Use as many sheets as necessary)***Complete if Known**

Application Number	N/A
Filing Date	Herewith
First Named Inventor	SUH, Pann-Ghill
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	20010-21USA

Sheet 1 of 1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	BAE ET AL., "Differential Activation of Formyl Peptide Receptor-Like 1 by Peptide Ligands," Journal of Immunology, 171:12 6807-6813 (2003).	
	C2	BAE ET AL., "Differential Activation of Formyl Peptide Receptor Signlaing by Peptide Ligands," Molecular Pharmacology, 64:4 841-847 (2003).	
	C3	BAE ET AL., "Identification of Peptides That Antagonize Formyl Peptide Receptor-Like 1-Mediated Signaling," Journal of Immunology, 173:1 607-614 (2004).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.